Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,812 shares of the medical equipment provider’s stock after selling 1,930 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Zimmer Biomet were worth $3,218,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the third quarter worth approximately $28,000. Crewe Advisors LLC bought a new position in Zimmer Biomet during the first quarter valued at about $31,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the third quarter worth about $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $43,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.5 %

ZBH stock opened at $109.31 on Thursday. The firm has a market cap of $21.76 billion, a PE ratio of 20.78, a PEG ratio of 2.04 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The company has a fifty day simple moving average of $106.65 and a 200 day simple moving average of $109.86. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.65 earnings per share. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is 18.25%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Canaccord Genuity Group reduced their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. Wells Fargo & Company upped their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Wolfe Research began coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Finally, Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.